Investment
Features
FeesSafety
Academy
More
Pluang+

Compare INNIO N.V. Ordinary Shares (INIO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

INNIO N.V. Ordinary SharesTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

INNIO N.V. Ordinary Shares vs Recursion Pharmaceuticals Inc — how do they compare? INNIO N.V. Ordinary Shares trades at $15.9 (market cap $12.38B), while Recursion Pharmaceuticals Inc trades at $3.62 (market cap $2.02B). The key difference: INNIO N.V. Ordinary Shares is far larger — about 6.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.

INIORXRX
Market Cap
$12.38B$2.02B
Volume
6,733,70818,610,436
Sector
IndustrialsHealth
52-Week High
$41.13$6.79
52-Week Low
$16.50$2.84
Typical Hold Time
0 Days22 Days
Enterprise Value
$14.04B$1.54B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

INNIO N.V. Ordinary Shares

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after beating expectations in previous quarters. Financials show significant losses with -961.97% net income margin and $644.76M net loss in 2025, though revenue grew to $74.26M. Recent strategic partnerships with Tempus and Roche highlight AI-driven drug discovery focus.

Outlook remains speculative with high-risk/high-reward profile. The AI drug discovery platform shows promise through partnerships, but profitability challenges and cash burn require careful monitoring. Analyst consensus leans cautious with 40% buy ratings amid substantial operational losses. Key catalysts include pipeline advancements and partnership milestones through 2028.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INIO
100% Buy0% Sell
Avg holding period · 0 Days
RXRX
27% Buy73% Sell
Avg holding period · 22 Days

About INNIO N.V. Ordinary Shares

INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.

Read more on INIO →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →